Onco Actu du 15 décembre 2015

	1. Biologie
Local protein factories make cancer cells motile [The Institute of Cancer Research] Our study has found that cancer cells need to be able to make the key proteins for movement locally within forward-facing projections, and that this is likely to be regulated by RNA-binding proteins which concentrate at the front of the cell.
Two Small RNAs, Often Missing from Cancer Cells, May Suppress Tumors [National Cancer Institute] Roughly one-third of all cancers involve mutant forms of RAS proteins. Understanding more about what regulates these mutant proteins could lead to new strategies for treating or even preventing these cancers.
	4. Dépistage, diagnostic et pronostic
The New Health Care: Even in Basic Health Decisions, You Can’t Screen Out Politics [NY Times] If we don’t want to leave things up to lawmakers or insurance companies, one of the few options left is to identify non-conflicted experts and let them make recommendations. As we’ve seen from recent events, Americans aren’t always satisfied with that either. Someone has to decide.
	4.2 Dép., diag. & prono. - Génome
Study uncovers hard-to-detect cancer mutations ​[Washington University in St. Louis] New research shows that current approaches to genome analysis systematically miss detecting a certain type of complex mutation in cancer patients’ tumors.
	4.7 Dép., diag. & prono. - Col de l'utérus
Five Factors Identify Subset of Patients With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab Treatment [AACR] “The factors are being of African-American ancestry and having a performance status of 1, pelvic disease, prior platinum-based treatment, and progression-free survival of less than one year."
	5.10 Traitements - Essais
Clinical trials are subjecting cancer patients to too many biopsies, study finds [STAT] Cancer patients in clinical trials across the US are undergoing a slew of expensive, invasive biopsies with no clear benefits, according to an analysis published Monday in the Journal of Clinical Oncology.
	5.12 Immunothérapies
Cancer Immunotherapy ETF Offers High Growth Investing Potential [TheStreet] Immunotherapy is changing the way the medical community thinks about treating cancer. Brad Loncar, CEO of Loncar Investments, said Wall Street needs to follow suit and change the way it invests in cancer drug companies.
	5.2 Pharma
Amgen reacquires rights to three drugs from Glaxo in 48 countries [Reuters] The three Amgen drugs are the osteoporosis treatment Prolia; the related drug XGeva, used to prevent fractures in cancer that has spread to the bone, and Vectibix for advanced colorectal cancer.
	5.2.1 Pharma - Partenariats
Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program [BMS] The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
	5.4 Traitements - Economie
NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information [NICE] Specifically, the draft recommendations say that olaparib should be available for people only if they have had 3 or more courses of platinum-based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months is met by the company.
Drug approvals top 2014 high but R&D returns still struggle [Reuters] The mismatch between the rising number of drug approvals and falling returns reflects the fact that each new medicine is expected to yield significantly lower average sales, while costs are continuing to rise.
	6. Lutte contre les cancers
Cannabis & Cancer: Cause, Cure, Conundrum [Colorado Cancer Blogs] Within two miles of the University of Colorado Cancer Center are at least seven recreational marijuana dispensaries with names like Pink House, Terrapin Care Station, Sweet Leaf, Lightshade and Starbuds. And the influence of what happens off campus doesn’t stay off campus. Our patients are using marijuana – some recreationally, some to alleviate the symptoms of cancer and cancer treatments, and some with the belief that cannabis and cannabis-based products could improve or cure their disease.
	6.1 Observation
Pregnancy does not increase risk of Hodgkin lymphoma recurrence [Karolinska Institutet] The present study included 449 women between the ages of 18 and 40 diagnosed with Hodgkin lymphoma between 1992 and 2009. The study investigated whether women who had responded successfully to treatment and subsequently became pregnant ran a higher risk of relapse than women who did not become pregnant.
	6.11 Patients
Woman with breast cancer gives birth prematurely to undergo treatment [The Guardian] After her initial treatment failed, doctors recommended she undergo intensive chemotherapy which could save her but put her unborn baby’s health at risk. Loughlin, a Metropolitan police officer from Portishead, north Somerset, decided that her only chance of survival was to give birth on Monday – 12 weeks early.
	6.3 Associations
Misleading analysis of charity spending: Our response [Cancer Research UK] "Charities like CRUK, which receive no government money, play a vital role in funding life-saving research and misleading stories such as the one published today risk undermining the trust that we work hard to sustain in all we do.”
	6.6 Publications
Cancer research pioneer Robert Weinberg corrected Oncogene paper [Retraction Watch] We’ve gotten feedback from readers asking why we cover corrections; we chose to flag this one because Weinberg has had such an impact on his field — he discovered the first tumor-causing gene in humans, as well as the first tumor-suppressor gene — and his papers are often highly cited.
	6.9 Controverses
Reporting Clinical Trials: Nothing Happens When Nothing Happens [In the Pipeline] The article says that the FDA’s own staff scientists have violated the reporting laws 75% of the time, although compared to (say) Stanford, at a solid 95% noncompliance, perhaps that’s not so bad.